According to the World Health Organization (WHO), “The number of global cancer deaths is projected to increase 45% from 2007 to 2030.” “In most developed countries, cancer is the second largest cause of death after cardiovascular disease, and epidemiological evidence points to this trend emerging in the less developed world.”
Imaging is a critical component of primary and secondary endpoints for oncology evaluation. ICON Medical Imaging is involved in endpoint analysis for Objective Response Rates, Best Overall Response, Time to Progression, Progression Free Survival and other related criteria in support of Phase I, II, and III clinical trials, including submissions for approved cancer therapies. ICON Medical Imaging’s role as a medical imaging and endpoint core laboratory is to help sponsors assess the effect of therapies by independent and rigorous assessment of clinical and imaging endpoints. ICON Medical Imaging accomplishes this through the use of:
Advanced Science
ICON Medical Imaging has significant experience in all imaging modalities used in Oncology including CT, MR, PET, Nuclear Medicine and X-Ray. ICON Medical Imaging provides personal, one-on-one interaction and consulting on the critical uses of imaging in your trials, including the medical, scientific and regulatory aspects. Our people are imaging experts, with deep clinical and scientific roots.
Experienced People
The significance of clearly understanding and addressing the nuances of medical imaging data are of particular importance in oncology research trials. ICON Medical Imaging encompasses this understanding; therefore, we offer the most experienced team in the industry.
Our senior management team has continuously pioneered the use of imaging for drug development for over 20 years. ICON Medical Imaging’s Oncology team includes:
- CT, MR, Nuclear Medicine and PET Imaging Specialists
- Oncology Nurses/Study Coordinators
- Oncologists
- Subspecialty Radiologists
- Biomedical Engineers
- Physicists
- Allied Support Personnel
Unlike other core labs, ICON Medical Imaging’s project managers and clinical staff are registered professional medical imaging technologists with hands-on clinical imaging experience; they are detail-oriented, reliable Oncology specialists.
Superior Technology
ICON Medical Imaging provides leading image management, the fastest blinded read setup in the industry, 21 CFR Part 11 compliant technology, and a complete image based knowledge management system; all designed to empower the sponsor with access to critical information anywhere, anytime.
ICON Medical Imaging provides access to image data and project management in a single system called MIRATM. MIRATM provides the ability to analyze all data in a fully electronic, 21 CFR Part 11 compliant environment with integrated eCRF capture. The combination of regulatory experience and technological innovation also facilitates fast blinded read setup. MIRATM was designed to facilitate sponsor timeline management by allowing up-to-the-minute access of dataflow and image reads.
When timing is critical, ICON Medical Imaging encourages the use of our Oncology Image Review System. Utilizing standard RECIST review criteria, ICON Medical Imaging delivers to the sponsor an Image Review Charter (IRC) and validated electronic case report form (eCRF) in two weeks from study start versus the industry standard of 12 weeks. Our Oncology Image Review System is 21 CFR Part 11 compliant; permitting efficient image data processing with minimal investment in setup time.
To learn more about how ICON Medical Imaging can help you with your next Oncology trial, contact us today.
